Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 8/20 | 0.54 |
| ▸ | PLA2G4A | P47712 | 1/20 | 0.42 |
| ▸ | PTGS2 | P35354 | 5/20 | 0.41 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.41 |
| ▸ | CNR2 | P34972 | 1/20 | 0.40 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.40 |
| ▸ | PLA2G2A | P14555 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | RGS12 | O14924 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3372448 | 0.90 | PTGDR2 (0.56) | PTGDR2PTGS2AKR1B1AKR1C3ALDH1A1 | |
| SCHEMBL2052563 | 0.87 | PTGDR2 (0.71) | PTGDR2PTGS2AKR1B1AKR1C3ALDH1A1 | |
| SCHEMBL3375010 | 0.81 | PTGDR2 (0.57) | PTGDR2PTGS2AKR1B1CNR2AKR1C3 | |
| SCHEMBL3370516 | 0.80 | PTGDR2 (0.55) | PTGDR2PTGS2AKR1B1CNR2AKR1C3 | |
| SCHEMBL3374154 | 0.80 | PTGDR2 (0.55) | PTGDR2PTGS2AKR1B1CNR2AKR1C3 | |
| SCHEMBL3372368 | 0.77 | PTGDR2 (0.76) | PTGDR2PLA2G4AAKR1B1CYP2C9 | |
| SCHEMBL2050711 | 0.77 | PTGDR2 (0.74) | PTGDR2AKR1B1AKR1C3LMNACYP1A2 | |
| SCHEMBL3373960 | 0.76 | PTGDR2 (0.70) | PTGDR2AKR1B1CYP2C9TSHR | |
| SCHEMBL1757891 | 0.76 | PTGDR2 (0.45) | PTGDR2AKR1B1ALDH1A1CYP2C9TSHR | |
| SCHEMBL3373433 | 0.74 | PTGDR2 (0.67) | PTGDR2AKR1B1CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1656347-B1 | SUBSTITUTED INDOLE DERIVATIVES FOR PHARMACEUTICAL COMPOSITION FOR TREATING RESPIRATORY DISEASES | ASTRAZENECA AB (SE) | 2010-10-13 | — | — | EP | disclosed |
| US-7709521-B2 | Substituted indole derivatives for pharmaceutical compositions for treating respiratory diseases | ASTRAZENECA AB (SE) | 2010-05-04 | — | — | US | disclosed |
| US-20060264444-A1 | Substituted indole derivatives for pharmaceutical compositions for treating respiratory diseases | ASTRAZENECA AB (SE) | 2006-11-23 | — | — | US | disclosed |
| EP-1656347-A1 | SUBSTITUTED INDOLE DERIVATIVES FOR PHARMACEUTICAL COMPOSITION FOR TREATING RESPIRATORY DISEASES | Astrazeneca AB (SE) | 2006-05-17 | — | — | EP | disclosed |
| WO-2005019171-A1 | SUBSTITUTED INDOLE DERIVATIVES FOR PHARMACEUTICAL COMPOSITION FOR TREATING RESPIRATORY DISEASES | ASTRAZENECA AB (SE) | 2005-03-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060264444-A1 | Substituted indole derivatives for pharmaceutical compositions for treating respiratory diseases | IDO1, IDO2, TPH1 | PTGDR2 303/4885PLA2G4A 1368/4885PTGS2 338/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.